60 Degrees Pharmaceuticals
SXTP
7 hedge funds and large institutions have $127K invested in 60 Degrees Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
133% more funds holding
Funds holding: 3 → 7 (+4)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
73% less capital invested
Capital invested by funds: $467K → $127K (-$341K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$46.7K |
| 2 |
VF
Virtu Financial
New York
|
+$27.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$11.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.24K |
| 5 |
Renaissance Technologies
New York
|
+$5.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$104K |
| 2 |
CBT
Central Bank & Trust
Lexington,
Kentucky
|
-$41.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CBT
1
Central Bank & Trust
Lexington,
Kentucky
| $69.7K | -$41.4K | -371 | -25% |
|
|
2
Citadel Advisors
Miami,
Florida
| $26.3K | +$46.7K | +419 | New |
|
|
VF
3
Virtu Financial
New York
| $16K | +$27.7K | +248 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $6.31K | +$11.3K | +101 | New |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3.54K | +$6.24K | +56 | New |
|
|
6
Renaissance Technologies
New York
| $3K | +$5.8K | +52 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1.81K | +$1.78K | +16 | +123% |
|
8
Wells Fargo
San Francisco,
California
| $14 | – | – | – |
|
|
9
Walleye Capital
New York
| – | -$104K | -428 | Closed |
|
SXTP Hedge Fund Activity: Q1 2024 in Review
7 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in 60 Degrees Pharmaceuticals (SXTP) for Q1 2024, worth a combined $127K — down 73% from $467K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SXTP positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $46.7K. The largest seller was Walleye Capital, exiting entirely with an estimated $104K sold.
- 7 institutional investors held 60 Degrees Pharmaceuticals (SXTP) as of Q1 2024, up from 3 in Q4 2023.
- Funds reported $127K of 60 Degrees Pharmaceuticals stock for Q1 2024, down 73% quarter-over-quarter.
- 5 funds opened new 60 Degrees Pharmaceuticals positions in Q1 2024 and 1 closed out, a net change of +4 holders.
- The largest 60 Degrees Pharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $46.7K added.
- The largest 60 Degrees Pharmaceuticals seller in Q1 2024 was Walleye Capital, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2024.